Novel therapy for nasopharyngeal carcinoma--where are we.

摘要: Nasopharyngeal carcinoma (NPC) is endemic in Southern China, and the South-East Asia including Hong Kong. We still see patients recur after primary treatment with radiotherapy or chemo-irradiation. Management of nasopharyngeal remains one biggest clinical challenges. There have been breakthroughs early detection, diagnosis, multi-modality also disease monitoring for NPC. Systemic has crucial to management locally advanced metastatic With advent molecular targeted therapy personalized medicine, novel therapies based on targets NPC become focus research development over last decade. Furthermore, as tightly associated Epstein-Barr virus (EBV) infection, role tumor-associated viral antigens renders it an appealing candidate cellular immunotherapy. This a review recent evolving concerted efforts success from our translational systemic potential immunotherapy which may offer further benefit living The scientific basis latest published results relevant trials are highlighted, demonstrating ongoing battle against indeed most fascinating successes head neck oncology.